AXDX Oct 2019 15.000 put

OPR - OPR Delayed Price. Currency in USD
0.1000
0.0000 (0.00%)
As of 12:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1000
Open0.1000
Bid0.0000
Ask0.1500
Strike15.00
Expire Date2019-10-18
Day's Range0.1000 - 0.1000
Contract RangeN/A
Volume4
Open Interest622
  • Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
    PR Newswire

    Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

    "We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest™ BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations. The first of the studies is RAPIDS-GN (ClinicalTrials.gov # NCT03218397), a randomized controlled trial conducted at Mayo Clinic and UCLA.  RAPIDS-GN focused on Gram-negative bacteremia and randomized patients to be tested by the BC kit or legacy methods. The study met the primary endpoint of therapy optimization, reporting time to first Gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 hours vs. 42.1 hours, p

  • Just Two Stocks Turned Pennies Into Billions
    Investor's Business Daily

    Just Two Stocks Turned Pennies Into Billions

    The idea of turning pocket change into a billion bucks is alluring. But this mirage of penny stocks is also nearly a complete fantasy.

  • Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%
    Zacks

    Accelerate Diagnostics (AXDX) Jumps: Stock Rises 9.4%

    Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
    PR Newswire

    Accelerate Diagnostics Highlights Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

    TUCSON, Ariz., Sept. 18, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. The first of these studies is the ARLG-sponsored RAPIDS-GN clinical study conducted at Mayo Clinic and UCLA.

  • Thomson Reuters StreetEvents

    Edited Transcript of AXDX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Accelerate Diagnostics Inc Earnings Call

  • Accelerate Diagnostics (AXDX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Accelerate Diagnostics (AXDX) Q2 2019 Earnings Call Transcript

    AXDX earnings call for the period ending June 30, 2019.

  • Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

    Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 5.00% and -33.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Accelerate Diagnostics Names Jack Phillips Chief Operating Officer
    PR Newswire

    Accelerate Diagnostics Names Jack Phillips Chief Operating Officer

    TUCSON, Ariz., Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Jack Phillips has been appointed Chief Operating Officer.  Mr. Phillips joins Accelerate from Roche Diagnostics, the world's leading diagnostics company. Lawrence Mehren, President and Chief Executive Officer of Accelerate Diagnostics, commented, "We are thrilled to have an accomplished commercial leader of Jack's caliber join our team. This is an exciting time for Accelerate as we approach an inflection point in our commercial growth.

  • Accelerate Diagnostics Reports Second Quarter 2019 Financial Results
    PR Newswire

    Accelerate Diagnostics Reports Second Quarter 2019 Financial Results

    TUCSON, Ariz. , Aug. 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2019 . "We achieved mixed results in ...

  • Some Accelerate Diagnostics (NASDAQ:AXDX) Shareholders Are Down 19%
    Simply Wall St.

    Some Accelerate Diagnostics (NASDAQ:AXDX) Shareholders Are Down 19%

    It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...

  • Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Accelerate Diagnostics Schedules Call to Review Second Quarter 2019 Results
    PR Newswire

    Accelerate Diagnostics Schedules Call to Review Second Quarter 2019 Results

    TUCSON, Ariz. , July 8, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that it will report financial results for the second quarter of 2019 after the market close on Thursday, ...

  • Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?
    Simply Wall St.

    Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Markit

    See what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.

    Accelerate Diagnostics Inc NASDAQ:AXDXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AXDX are favorable, with net inflows of $1.09 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Accelerate Diagnostics to Present at the William Blair Growth Stock Conference on June 6, 2019
    PR Newswire

    Accelerate Diagnostics to Present at the William Blair Growth Stock Conference on June 6, 2019

    TUCSON, Ariz., May 24, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Chief Executive Officer, Larry Mehren, and Chief Financial Officer, Steve Reichling will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019 at 12:00 p.m. Central Time. A live webcast of the presentation will be accessible through the company's investor relations website at ir.axdx.com. Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.

  • Thomson Reuters StreetEvents

    Edited Transcript of AXDX earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Accelerate Diagnostics Inc Earnings Call

  • InvestorPlace

    You Can Get Buy Signals From Short Selling

    You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.

  • Accelerate Diagnostics (AXDX) Q1 2019 Earnings Call Transcript
    Motley Fool

    Accelerate Diagnostics (AXDX) Q1 2019 Earnings Call Transcript

    AXDX earnings call for the period ending March 31, 2019.

  • Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

    Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.98% and -17.57%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Accelerate Diagnostics: 1Q Earnings Snapshot

    The Tucson, Arizona-based company said it had a loss of 40 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • Accelerate Diagnostics Reports First Quarter 2019 Financial Results
    PR Newswire

    Accelerate Diagnostics Reports First Quarter 2019 Financial Results

    TUCSON, Ariz. , May 9, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter ended March 31, 2019 . "We are pleased with our continued ...

  • Did Hedge Funds Drop The Ball On Accelerate Diagnostics Inc (AXDX) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Accelerate Diagnostics Inc (AXDX) ?

    "Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Accelerate Diagnostics (AXDX) to Report a Decline in Earnings: What to Look Out for

    Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.